ReproGO
ReproGo is a biotechnology company specializing in regenerative medicine and vascular diseases. Their mission is to provide therapies for incurable conditions and disabilities resulting from the deterioration or loss of blood vessels by restoring blood vessel function. They utilize a powerful AI-powered platform called Cell'N'Go™ to create any human cell type with speed, accuracy, and reliability. Their key product, RCells™, are precision-engineered human iPSC-derived vascular cells designed for research and drug discovery, offering superior purity, stability, and functionality compared to alternatives. The company is an award-winning regenerative medicine company, originating from Queen's University Belfast, founded by Prof. Andriana Margariti and led by CEO Dr. Sophia Kelaini, with a history of research spanning over two decades in vascular dysfunction. ReproGo aims to progress donor-independent, allogeneic cell replacement therapy, minimizing animal testing and promoting eco-friendly biomanufacturing.
ReproGO
ReproGo is a biotechnology company specializing in regenerative medicine and vascular diseases. Their mission is to provide therapies for incurable conditions and disabilities resulting from the deterioration or loss of blood vessels by restoring blood vessel function. They utilize a powerful AI-powered platform called Cell'N'Go™ to create any human cell type with speed, accuracy, and reliability. Their key product, RCells™, are precision-engineered human iPSC-derived vascular cells designed for research and drug discovery, offering superior purity, stability, and functionality compared to alternatives. The company is an award-winning regenerative medicine company, originating from Queen's University Belfast, founded by Prof. Andriana Margariti and led by CEO Dr. Sophia Kelaini, with a history of research spanning over two decades in vascular dysfunction. ReproGo aims to progress donor-independent, allogeneic cell replacement therapy, minimizing animal testing and promoting eco-friendly biomanufacturing.